ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MIRA / news
IMMP (47) CRVO (28) QNRX (37) ATOS (33) ⌘ Pro Terminal →

Why MIRA Stock dropped -2.06% Today — RQD Quant Desk Flash

$0.54 -2.06% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.54

MIRA Pharmaceuticals Inc. (MIRA) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $23.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MIRA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MIRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.54 (-2.06% 1D, market cap $23.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, MIRA ranks #574 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MIRA compare to IMMP and CRVO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MIRA carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMMP (Immutep Limited) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $22.6M) and CRVO (CervoMed Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $24.2M). Among the 5-stock peer group, MIRA leads on earnings multiple (N/A) while MIRA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MIRA?
▼

Per MIRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001904286), MIRA Pharmaceuticals Inc. generated $4.7M in revenue (+279.5% YoY), -$10.4M in net income, and -$4.7M in free cash flow against $11.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.54 (-0.56%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510036
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (9)Whales (8)SEC (10)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9.3% Base Target
$2 Bull$0 Base$0 Bear
📬 FREE MIRA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MIRA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY MIRA SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
44
Grade D$0.67-3% Next Q
Q2 (-2Q)
41
Grade D$0.65-15.4% Next Q
Q3 (-1Q)
39
Grade E$0.55-1.8% Next Q
Current
36
Grade D-$0.54-8.3% Hist 90D α
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MIRA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MIRA currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.73) and Max Pain ($0.57) forces dealer call-delta covering toward $1.84.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MIRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MIRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why MIRA Stock dropped -2.06% Today — RQD Quant Desk Flash

MIRA Pharmaceuticals Inc. (MIRA) dropped -2.06% to $0.54, trading at 2% of its 52-week range ($0.51 – $1.75). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 2% of its 52-week range ($0.51 – $1.75) with RSI-14 at 35.7 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.54 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live MIRA Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MIRA)

  • ✓Walkthrough of MIRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MIRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.57%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.57H $0.57L $0.54C $0.54VOL 207.8K
RES: $1.03SUP: $0.50SMA50: $0.73SMA200: $0.96
$1.41$1.17$0.92$0.68$0.43RES $1.03SUP $0.50$0.542026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MIRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MIRA Butterfly Map → + Track MIRA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +279.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MIRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MIRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MIRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MIRA)

Health Care Rank #574 of 1015 ⚔️ IMMP vs MIRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MIRA vs. IMMP, CRVO, QNRX, ATOS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, MIRA Pharmaceuticals Inc. (MIRA) ranks #574 by composite RQD confidence (36/100, grade D-) and #821 by equity capitalization ($23.0M). Within this direct 5-issuer industry benchmark cohort, MIRA leads on earnings valuation at N/A trailing P/E, while MIRA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IMMP currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with MIRA at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MIRA ACTIVE
MIRA Pharmaceuticals Inc.
D- 36/100 — — -35.0% -2.06% $23.0M Benchmark Subject
IMMP
Immutep Limited
D 47/100 — — — +0.33% $22.6M /immp-vs-mira →
CRVO
CervoMed Inc.
E 28/100 — — -35.0% +2.50% $24.2M /crvo-vs-mira →
QNRX
Quoin Pharmaceuticals Ltd.
D- 37/100 — — -35.0% -11.45% $21.8M /qnrx-vs-mira →
ATOS
Atossa Therapeutics Inc.
E 33/100 — — -35.0% +5.99% $21.7M /atos-vs-mira →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001904286 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), MIRA Pharmaceuticals Inc. (MIRA) reported GAAP revenue of $4.7M (+279.5% vs. FY2024 revenue of $1.2M , and -91.4% cumulative change since FY2023) , GAAP net income of -$10.4M, operating cash flow of -$4.7M, and free cash flow of -$4.7M (+16.2% YoY). On the balance sheet, MIRA closed FY2025 with $11.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $4.7M -$10.4M -$4.7M -$4.7M $11.1M —
FY2024 (FY) 2024-12-31 $1.2M -$7.9M -$5.6M -$5.6M $2.9M —
FY2023 (FY) 2023-12-31 $53.9M -$12.0M -$4.5M -$4.5M — —

3. MIRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MIRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.54 (-2.06% 1D, market cap $23.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, MIRA ranks #574 in composite RQD confidence.

How does MIRA compare to IMMP and CRVO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MIRA carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMMP (Immutep Limited) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $22.6M) and CRVO (CervoMed Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $24.2M). Among the 5-stock peer group, MIRA leads on earnings multiple (N/A) while MIRA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MIRA?

Per MIRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001904286), MIRA Pharmaceuticals Inc. generated $4.7M in revenue (+279.5% YoY), -$10.4M in net income, and -$4.7M in free cash flow against $11.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MIRA trading relative to its 50-day, 200-day, and 52-week technical levels?

MIRA last traded at $0.54 (-2.06% on volume of 132,204 shares), positioning the stock -26.03% below its 50-day simple moving average ($0.73) and -43.75% below its 200-day simple moving average ($0.96). Across its 52-week range of $0.51 to $1.75, MIRA sits at the 2.4% percentile with a 14-day RSI of 35.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.61).

Direct Sub-Reports: MIRA RQD Cockpit MIRA 12M Forecast MIRA Earnings & Move MIRA Dividends & DRIP MIRA Insiders & 13F MIRA Whale Options MIRA Profit Sankey MIRA News & Why
ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ SEC XBRL & RQD VERIFIED

MIRA — MIRA Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

MIRA Pharmaceuticals Inc. (MIRA) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.54 (-2.06% 1D, market capitalization $23.0M).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -19.41%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

MIRA Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the news wire, the company's recent items reference preclinical data for an oral obesity drug and an oral pain drug, plus weight-loss data for its SKNY-1 compound.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), MIRA Pharmaceuticals Inc. (MIRA) reported $4.7M in annual revenue (up from $1.2M in FY2024, +279.5% YoY) and -$10.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($53.9M revenue, -$12.0M net income) through FY2025, MIRA scaled operating cash flow to -$4.7M and free cash flow to -$4.7M, backed by $11.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -19.41% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $0.51 – $1.75 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlations: — The investor implication is that the source data cannot map how a development setback or positive readout would propagate to partners or peers, so second-order ripples cannot be assessed from this dataset.

  • Key Question #1: Can MIRA sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $4.7M and free cash flow of -$4.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is MIRA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MIRA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for MIRA Pharmaceuticals Inc. (MIRA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MIRA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MIRA Bull vs. Bear Conversation Board — What's Your Call at $0.54?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MIRA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MIRA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $0.70 (+27.3%)
📌 Pinned Debate

The stock trades near its 52-week low at $0.57 with $6.3M in cash and a series of preclinical data releases that could serve as catalys

The stock trades near its 52-week low at $0.57 with $6.3M in cash and a series of preclinical data releases that could serve as catalysts.. When you look under the hood at MIRA, Fundamental Cash Engine is 9/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (8/20) has been quietly accumulating below $1.75. My 12M target is $0.70.

EarningsSniper 🐂 BULL

Both sides have a point here — MIRA's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $0.42 (-23.6%)
Spot @ $0.55

Negative ROIC of -35%, a negative FCF yield of -19.41%, and an insider conviction score of 3/20 leave the company with weak fundamental

Negative ROIC of -35%, a negative FCF yield of -19.41%, and an insider conviction score of 3/20 leave the company with weak fundamentals and little insider support.. Look at the math on MIRA: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $0.48 before getting long.

LIVE TAPE